NEW YORK (GenomeWeb News) – BioMerieux subsidiary BioTheranostics said today that it has signed up Spain's Ferrer InCode to market its molecular diagnostic cancer test in Spain, Portugal, Greece, and Venezuela.

Under the agreement, Ferrer InCode will market BioTheranostics’ Theros CancerTYPE ID molecular cancer classifier. The test is a 92-gene assay that oncologists may use in their efforts to manage patients whose primary tumor sites are not known, otherwise known as cancers of unknown primary origin, or CUP.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.